Bortezomib
Adenosquamous Cell Lung Cancer
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Adenosquamous Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
Carboplatin NRG Oncology | Phase 3 | BB |
Gefetinib National Cancer Institute (NCI) | Phase 3 | BB |
Vinorelbine National Cancer Institute (NCI) | Phase 3 | BB |
SHARK CARTILAGE EXTRACT National Cancer Institute (NCI) | Phase 3 | BB |
View all 22 →
Same molecule, other indications
Bortezomib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →